Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia
Condition(s) studied
Investigational drug(s) / intervention(s)
Riboflavin 0.1% ophthalmic solution and pulsed light: Use of riboflavin 0.1% eye drops and pulsed 18 milliwatt/cm2 ultraviolet A light for 10 minutes
Riboflavin 0.1% ophthalmic solution and non-pulsed light: Use of riboflavin 0.1% eye drops and non-pulsed 9 milliwatt/cm2 ultraviolet A light for 10 minutes
Study summary
This randomized study compares 2 variations of corneal crosslinking for treatment of keratoconus or corneal ectasia.
Eligibility
Primary outcome measure(s)
- Change in maximum keratometry — 6 months
assessed with corneal tomography
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Price Vision Group | Indianapolis | Indiana | Recruiting |
More Price Vision Group trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07841470 on ClinicalTrials.gov ↗ ← All trials in the USA